Language:
Cosentex: First-Line Systemic

Welcome

Welcome to the Cosentyx website

Cosentyx is the only fully human anti-IL-17A to be approved in Europe for the first-line systemic treatment of patients with moderate-to-severe plaque psoriasis, and is also indicated for patients with psoriatic arthritis and ankylosing spondylitis 1

Find out how Cosentyx can help your patients with psoriasis achieve lasting clear or almost clear skin with monthly subcutaneous self-injections1

Strength

~ 8/10 patients achieve PASI 90 at week 162

Find out more

Sustainability

90% of PASI 90 response at week 16 seen at week 521

Find out more
90%

Safety

Well tolerated in over 6,800 patients1

Find out more
6800

References

  1. Cosentyx Summary of Product Characteristics, May 2016.
  2. Thaçi D et al. J Am Acad Dermatol 2015; 73(3): 400-409.
  3. European Medicines Agency. Guideline On Clinical Investigation Of Medicinal Products Indicated For The Treatment Of Psoriasis, November 2004.
  4. Girolomoni G, et al. Br J Dermatol 2012; 167(4): 717-24.

NP4 code: GLDEIM/AIN457A/0356

Terms of use Privacy policy About cookies

© 2016 Novartis Pharma